Mythic Therapeutics, Inc.

Mythic is thrilled that our Director of Program Management, Kate Lai, will be participating in a presentation at Clinical Trials in Oncology East Coast tomorrow, July 10th, at 11:00 AM ET! Join Kate as she dives into the critical role of strong partnerships in advancing cancer research. She'll be joined by Troy DeSelms of Catalyst Oncology for a discussion you won't want to miss.

Be sure to tune in tomorrow as our COO, Sandra Poole, shares strategies for navigating the complexity of the #ADC manufacturing environment during BioProcess Online Live’s virtual panel.    She will be joined by Amy Johnson, Ph.D., VP of Medical Affairs at Vincerx Pharma, DeciBio Project Leader, Joe Daccache, Ph.D., and Bioprocess Online's Chief Editor and panel host, Matthew Pillar.    Learn more about the panel and register here: https://bit.ly/4cBIWsY. 

Our Phase 1 KisMET-01 #clinicaltrial evaluating MYTX-011, our investigational cMET-targeting #ADC for patients with previously treated, locally advanced or metastatic #NSCLC, is now underway in 7 countries globally. We are driving therapeutic innovation as we strive to make a difference in the lives of patients worldwide.       To learn more about the study, visit: https://bit.ly/47MGJrD  

At Mythic, we’re pioneering new pathways in #cancer treatment. Using our FateControl technology, our #ADCs are designed for increased internalization in targeted tissues, thereby providing enhanced efficacy and reduced toxicity against a broad range of tumor types.   Visit our website to learn more about how our pipeline of self-navigating ADCs have the potential to treat a broader patient population than previously possible: https://mythictx.com/ 

Meet Chad Kitchen, PhD, JD, our Vice President, Legal. Chad’s role in the #lifescience industry has evolved from scientist to intellectual property specialist to legal generalist. He’s played a central role in helping to shape and drive Mythic’s IP strategy, and through broader legal support efforts, he has helped to build strong partnerships both internally and with our key partners and vendors.    Together, as we press forward in our pursuit of improving health outcomes for #cancer patients, we are so fortunate to have Chad as a vital member of our team. Learn more about what fuels Chad’s work at Mythic below.       #MeetMythic #MythicProud   

#ICYMI Our President and CEO, George Eliades, Ph.D., attended the Biotechnology Innovation Organization’s Annual Convention last week to connect with fellow leaders in the industry and share insights on a panel discussion around novel ways of co-opting existing biological processes to drug cancer and other diseases. It was a fantastic opportunity to share successes, learnings and new ideas. What an honor to be shaping the future of biotech together! #BIO2024 #ADCs 

At Mythic, our #ADCs are designed to deliver more of any given dose of ADC to tumor cells and less to healthy cells, thereby increasing efficacy while minimizing unwanted toxicity. Read as our President and CEO, George Eliades, Ph.D., discusses how we are developing next-generation ADCs with the potential to target and treat cancers across a broader patient population in PharmaVoice’s latest Biotech Spotlight piece by Alexandra P..     Read the full article here:  https://bit.ly/3RbgtSk 

Last week, our team presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Thank you to everyone who connected with us on-site as we showcased new results from our ongoing #clinicaltrial of MYTX-011, our cMET-targeting #ADC. We look forward to continuing the dialogue as we work to drive innovation in ADCs for #cancer patients.     Missed our presentation? View our full poster here: https://bit.ly/4ec8rCv    #ASCO24 #ASCO2024 

At Mythic, we take a unique approach when it comes to developing our novel #ADCs. By prioritizing the #antibody component over the linker or payload, we strive to enhance payload delivery to #cancer cells while minimizing exposure to normal cells.     Our Chief Scientific Officer and Co-Founder, Brian Fiske, delves deeper into this strategy, discussing how it propelled the development of our novel ADC candidate, MYTX-011, with host, Matthew Pillar, on Bioprocess Online’s #BusinessOfBiotech Podcast. Listen here: https://bit.ly/3Kd8ccH. 

Tomorrow, join our President and CEO, George Eliades, Ph.D., at #BIO2024 for a panel discussion around novel ways of co-opting existing biological processes to drug cancer and other diseases. Learn more: https://bit.ly/4dbnlbS